title: Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
authors.affiliation: a Cancer Molecular Diagnostics , St. James's Hospital , Dublin , Ireland.
authors.forename: Mireille
authors.initials: M
authors.lastname: Crampe
authors.affiliation: b Department of Haematology , Sligo General Hospital , Sligo , Ireland.
authors.forename: Fatima
authors.initials: F
authors.lastname: Shakkak
authors.affiliation: c Department of Clinical Genetics , Our Lady's Children's Hospital , Dublin , Ireland.
authors.forename: Johanna
authors.initials: J
authors.lastname: Kelly
authors.affiliation: b Department of Haematology , Sligo General Hospital , Sligo , Ireland.
authors.forename: Andrew
authors.initials: A
authors.lastname: Hodgson
authors.affiliation: a Cancer Molecular Diagnostics , St. James's Hospital , Dublin , Ireland.
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Langabeer
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D023061:Gene Order; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014158:Transcription, Genetic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib